STOCK TITAN

Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Soleno Therapeutics, Inc. announces CEO presentation at TD Cowen 44th Annual Healthcare Conference, offering insights into rare disease therapeutics development.
Positive
  • None.
Negative
  • None.

REDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024, at 1:30 PM Eastern Time.

A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578


FAQ

When will Anish Bhatnagar present at the TD Cowen 44th Annual Healthcare Conference?

Anish Bhatnagar will present on Monday, March 4, 2024, at 1:30 PM Eastern Time.

Where can I access the live audio webcast and replay of the presentation?

The live audio webcast and replay will be available in the Investors section on Soleno Therapeutics' website at www.soleno.life.

What is Soleno Therapeutics' ticker symbol?

Soleno Therapeutics' ticker symbol is SLNO.

Soleno Therapeutics, Inc.

NASDAQ:SLNO

SLNO Rankings

SLNO Latest News

SLNO Stock Data

1.64B
13.17M
2.06%
97.44%
8.5%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About SLNO

soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.